Stocks Health care KROS
NASDAQ · Health careKeros Therapeutics, Inc. (KROS)
Keros Therapeutics, Inc. brought in $40.8M of revenue over the twelve months to September 30, 2026, down 83.5% from a year earlier. It posted a net loss of $61.7M. Operating cash flow minus capital spending left $106M of free cash flow in fiscal 2025. At September 30, 2026 it held $259.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Keros Therapeutics, Inc.
- Net worth
- Keros Therapeutics, Inc. has a market value (market cap) of $181.8M at the latest share price, and shareholders' equity of $279.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $244.1M (+6,775.0% year on year), with net income of $87M. Over the 12 months to September 30, 2026: revenue $40.8M, net loss $61.7M.
- Cash flow
- In fiscal 2025 operations brought in $107.5M of cash; after $1.6M of capital spending, free cash flow was $106M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Keros Therapeutics, Inc.'s next report is expected around March 3, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Keros Therapeutics, Inc. does
Keros Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker KROS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $244.1M | $87M | $2.30 | $106M |
| 2024 | $3.6M | -$187.4M | -$5.00 | -$162.8M |
| 2023 | $151K | -$153M | -$5.20 | -$127M |
| 2022 | $0 | -$104.7M | -$4.15 | -$71.3M |
| 2021 | $20.1M | -$58.7M | -$2.52 | -$63.2M |
| 2020 | $0 | -$45.4M | -$2.93 | -$37.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where KROS ranks in Health care
Latest SEC filings
What Keros Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 181% to $40M versus the same quarter last year; diluted EPS $0.70 versus -$0.18.
- November 5, 2026
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- September 29, 2026
- September 28, 2026
- September 11, 2026Form DEL AM filing DEL AM
- September 10, 2026
- September 8, 2026Other event 8-K
- August 3, 2026
What is KROS worth? A DCF from its reported cash flow
Insider trades
What the people running Keros Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $10.3K and sold $101.1K worth of shares in the last 90 days. 6% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 18, 2026 | Newton Charles W.Director | Soldpre-planned (10b5-1) | 551 | $5.7K |
| August 18, 2026 | Lerner Lorena RaquelChief Scientific Officer | Sold | 3,568 | $36.7K |
| August 18, 2026 | Cho EstherChief Legal Officer | Sold | 4,485 | $46.2K |
| August 18, 2026 | Tanini AnnitaCorp. Controller & VP, Finance | Sold | 1,224 | $12.6K |
| August 17, 2026 | Bienaime Jean JacquesDirector | Bought | 1,000 | $10.3K |
| July 15, 2026 | Bienaime Jean JacquesDirector | Bought | 1,000 | $10.6K |
| July 1, 2026 | Prener AnneDirector | Received as pay | 13,786 | - |
| June 15, 2026 | Bienaime Jean JacquesDirector | Bought | 1,000 | $10.2K |
Who owns KROS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Nantahala Capital Management, LLC13G, passive with 2 related filers | 6.9% | May 15, 2026 |
| BlackRock Portfolio Management LLC13G, passive | 5.7% | July 17, 2026 |
Largest institutional holders
Insiders
14 insiders reported holding 869,165 shares in total, about $8M at the last price.
| Holder | Shares |
|---|---|
| Seehra JasbirCHIEF EXECUTIVE OFFICER, Director | 440,708 |
| Knowles JuliusDirector | 113,191102,233 held indirectly |
| Tanini AnnitaCorp. Controller & VP, Finance | 45,144 |
| Orbimed Advisors LLCDirector | 45,05745,057 held indirectly |
| Gordon Carl LDirector | 45,05745,057 held indirectly |
| Regnante KeithCHIEF FINANCIAL OFFICER | 39,261 |
| Cho EstherChief Legal Officer | 35,770 |
| Lerner Lorena RaquelChief Scientific Officer | 27,559 |
| Bienaime Jean JacquesDirector | 19,592 |
| Prener AnneDirector | 13,786 |
Questions about KROS
What does Keros Therapeutics, Inc. do?
Keros Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as KROS. Its shares trade on NASDAQ under the ticker KROS.
What is Keros Therapeutics, Inc.'s net worth?
Keros Therapeutics, Inc. has a market value (market cap) of $181.8M at the latest share price, and shareholders' equity of $279.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Keros Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $61.7M on revenue of $40.8M.
How much revenue does Keros Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 Keros Therapeutics, Inc. reported revenue of $40.8M. That is 83.5% less than a year earlier.
When did Keros Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Keros Therapeutics, Inc.'s next earnings report?
Keros Therapeutics, Inc.'s next report is expected around March 3, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare KROS with
Follow KROS
Get an email when Keros Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Keros Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.